Coverage
-
May 02, 2011
A New Jersey federal judge on Monday signed off on a joint stipulation of dismissal of AstraZeneca Pharmaceuticals LP’s case alleging Biovail Corp. infringed its patents by seeking to launch a generic version of AstraZeneca’s popular treatment for bipolar disorder and schizophrenia, Seroquel XR.
2 other articles on this case.
View all »